Prof. Klusmann and Prof. Heckl on the news explaining new therapy options for pediatric AML

Leukemia Research on Television

On the latest episode of a regional news segment on SAT.1 Prof. Klusmann and Prof. Heckl were featured giving a quick insight onto exploiting micro-RNA as therapeutic option for AML patients. The interview gives a short summary on our latest paper about miR-193b: We describe how counteracting the downregulation of miR-193b can abrogate leukemic growth both in vitro and in vivo. To counter the downregulation of miR-193b, found across pediatric and adult AML, liquid nanoparticle (LNPs) can be used to allow introduction of RNAs into leukemic blasts. MicroRNA mimics are encapsulated in LNPs, which are then able to fuse with the leukemic cells and allow the RNA to enter the cells, to artificially increase the presence of said microRNAs inducing an anti-leukemic effect.

Watch the full segment for yourself online:

Or read more about miR-193b under:

Issa, H., et al. Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias. Leukemia 37, 1583–1587 (2023).

Bhayadia R, et al. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. J Clin Oncol. 2018 Apr 1;36(10):1007-1016. doi: 10.1200/JCO.2017.75.2204.



Back to blog overview

Other Blogposts